200 related articles for article (PubMed ID: 24777112)
1. Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy.
Ong CA; Shannon NB; Ross-Innes CS; O'Donovan M; Rueda OM; Hu DE; Kettunen MI; Walker CE; Noorani A; Hardwick RH; Caldas C; Brindle K; Fitzgerald RC
J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24777112
[TBL] [Abstract][Full Text] [Related]
2. TRIM44 promotes human esophageal cancer progression via the AKT/mTOR pathway.
Xiong D; Jin C; Ye X; Qiu B; Jianjun X; Zhu S; Xiang L; Wu H; Yongbing W
Cancer Sci; 2018 Oct; 109(10):3080-3092. PubMed ID: 30098109
[TBL] [Abstract][Full Text] [Related]
3. TRIM44 activates the AKT/mTOR signal pathway to induce melanoma progression by stabilizing TLR4.
Wei CY; Wang L; Zhu MX; Deng XY; Wang DH; Zhang SM; Ying JH; Yuan X; Wang Q; Xuan TF; He AQ; Qi FZ; Gu JY
J Exp Clin Cancer Res; 2019 Mar; 38(1):137. PubMed ID: 30922374
[TBL] [Abstract][Full Text] [Related]
4. TRIM44 promotes proliferation and metastasis in non‑small cell lung cancer via mTOR signaling pathway.
Xing Y; Meng Q; Chen X; Zhao Y; Liu W; Hu J; Xue F; Wang X; Cai L
Oncotarget; 2016 May; 7(21):30479-91. PubMed ID: 27058415
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of TRIM44 contributes to malignant outcome in gastric carcinoma.
Kashimoto K; Komatsu S; Ichikawa D; Arita T; Konishi H; Nagata H; Takeshita H; Nishimura Y; Hirajima S; Kawaguchi T; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
Cancer Sci; 2012 Nov; 103(11):2021-6. PubMed ID: 22862969
[TBL] [Abstract][Full Text] [Related]
6. TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling.
Kawabata H; Azuma K; Ikeda K; Sugitani I; Kinowaki K; Fujii T; Osaki A; Saeki T; Horie-Inoue K; Inoue S
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885545
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of long non-coding RNA DUXAP8 suppresses proliferation, metastasis and EMT by modulating miR-498 through TRIM44-mediated AKT/mTOR pathway in non-small-cell lung cancer.
Ji X; Tao R; Sun LY; Xu XL; Ling W
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3152-3165. PubMed ID: 32271433
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of TRIM44 is related to invasive potential and malignant outcomes in esophageal squamous cell carcinoma.
Kawaguchi T; Komatsu S; Ichikawa D; Hirajima S; Nishimura Y; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
Tumour Biol; 2017 Jun; 39(6):1010428317700409. PubMed ID: 28618928
[TBL] [Abstract][Full Text] [Related]
9. Methylation of NRN1 is a novel synthetic lethal marker of PI3K-Akt-mTOR and ATR inhibitors in esophageal cancer.
Du W; Gao A; Herman JG; Wang L; Zhang L; Jiao S; Guo M
Cancer Sci; 2021 Jul; 112(7):2870-2883. PubMed ID: 33931924
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of TRIM44 Inhibits the Proliferation and Invasion in Prostate Cancer Cells.
Tan Y; Yao H; Hu J; Liu L
Oncol Res; 2017 Sep; 25(8):1253-1259. PubMed ID: 28160462
[TBL] [Abstract][Full Text] [Related]
11. Sesamin exerts anti-tumor activity in esophageal squamous cell carcinoma via inhibition of TRIM44 and NF-κB signaling.
Wen L; Mao W; Xu L; Cai B; Gu L
Chem Biol Drug Des; 2022 Jan; 99(1):118-125. PubMed ID: 34411455
[TBL] [Abstract][Full Text] [Related]
12. TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway.
Zhou X; Yang Y; Ma P; Wang N; Yang D; Tu Q; Sun B; Xiang T; Zhao X; Hou Z; Fang X
J Neurooncol; 2019 Nov; 145(2):211-222. PubMed ID: 31605296
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
[TBL] [Abstract][Full Text] [Related]
14. A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor.
Yamada Y; Takayama KI; Fujimura T; Ashikari D; Obinata D; Takahashi S; Ikeda K; Kakutani S; Urano T; Fukuhara H; Homma Y; Inoue S
Cancer Sci; 2017 Jan; 108(1):32-41. PubMed ID: 27754579
[TBL] [Abstract][Full Text] [Related]
15. PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.
Wander SA; Zhao D; Besser AH; Hong F; Wei J; Ince TA; Milikowski C; Bishopric NH; Minn AJ; Creighton CJ; Slingerland JM
Breast Cancer Res Treat; 2013 Apr; 138(2):369-81. PubMed ID: 23430223
[TBL] [Abstract][Full Text] [Related]
16. Expression of tripartite motif-containing 44 and its prognostic and clinicopathological value in human malignancies:a meta-analysis.
Xiao G; Yang Q; Bao Z; Mao H; Zhang Y; Lin S
BMC Cancer; 2020 Jun; 20(1):525. PubMed ID: 32503466
[TBL] [Abstract][Full Text] [Related]
17. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
18. Tripartite Motif-Containing 44 is Involved in the Tumorigenesis of Laryngeal Squamous Cell Carcinoma, and its Expression is Downregulated by Nuciferine.
Li QH; Sui LP; Zhao YH; Chen BG; Li J; Ma ZH; Hu ZH; Tang YL; Guo YX
Tohoku J Exp Med; 2021 May; 254(1):17-23. PubMed ID: 34011804
[TBL] [Abstract][Full Text] [Related]
19. SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway.
Gen Y; Yasui K; Nishikawa T; Yoshikawa T
Cancer Sci; 2013 Jul; 104(7):810-6. PubMed ID: 23510069
[TBL] [Abstract][Full Text] [Related]
20. Trim44 facilitates the migration and invasion of human lung cancer cells via the NF-κB signaling pathway.
Luo Q; Lin H; Ye X; Huang J; Lu S; Xu L
Int J Clin Oncol; 2015 Jun; 20(3):508-17. PubMed ID: 25345539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
